Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Key benefits Why people compare it 1 FDA-approved as Egrifta for visceral adipose tissue reduction in lipodystrophy 2 15-18% VAT reduction demonstrated in two Phase 3 trials (N=816) 3 Improved triglycerides and waist circumference in key clinical data 4 Extended half-life (26-38 min) vs sermorelin due to trans-3-hexenoic acid modification 5 Improved verbal memory and executive function in older adults (Neurology study, p=0.03) 6 Physiological GH stimulation with intact pituitary negative feedback 7 Demonstrated 32% hepatic fat reduction in 12-month NAFLD trial 8 Well-characterized safety profile through FDA approval and post-marketing surveillance Deep research About Tesamorelin Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of native GHRH with a trans-3-hexenoic acid moiety conjugated to the tyrosine residue at position 1 via a carbamate linker
Our doctors design personalized treatment plans based on your digestive health response, symptom resolution, and overall wellness objectives, adjusting duration for optimal outcomes
As such, substantial data on BPC-157 administration in humans is lacking
This age-related decline is part of why researchers became interested in studying whether supplementing GHK-Cu might help maintain tissue repair capacity
Genome Biology 15, R27
![Cardiovascular disease continuum-GLP-1 action. Adapted from [46]](https://www.researchgate.net/publication/357072789/figure/fig1/AS:1146405179654167@1650335702879/Cardiovascular-disease-continuum-GLP-1-action-Adapted-from-46.png)
